Health Care
Anatara Lifesciences Ltd (ANR)
Anatara Lifesciences Ltd (ASX: ANR) is an Australian biotechnology company focused on developing and commercializing novel treatments for gastrointestinal diseases in humans and animals. Operating primarily from Australia, its key product is Anatara's CIC therapy for carbohydrate malabsorption. The company also explores veterinary applications.
Market Cap
A$3M
Shares on Issue
N/A
Price Chart
AI Analysis
Anatara Lifesciences is currently in a development phase with a market cap of A$3M, indicating its micro-cap and speculative nature. Recent performance has likely been driven by research milestones rather than revenue, given its pre-revenue status. Key metrics to watch include trial progression and funding announcements.
Growth outlook hinges on successful trial data for its CIC therapy, potential partnerships, and strategic expansion into the veterinary sector. Upcoming catalysts may include clinical trial results, regulatory approvals, or licensing agreements, guiding its strategic direction towards commercialization.
Bull Case
- • Successful clinical trial results for CIC therapy leading to rapid regulatory approval and market entry
- • Strategic partnership or licensing deal with a major pharmaceutical or animal health company
- • Expansion into the veterinary market proves highly profitable with quick uptake
Bear Case
- • Clinical trials for CIC therapy fail to meet endpoints, halting development
- • Difficulty in securing necessary funding to progress through clinical stages
- • Intense competition in both human and animal gastrointestinal treatment markets limits penetration
Recent Announcements
Application for quotation of securities - ANR
Conversion of Performance Rights
Appendix 4D & Half Year Report 31 December 2025
🚨 Price SensitiveAppendix 4D & Half Year Report 31 December 2025
FAQs
What does ANR do?
Anatara Lifesciences develops treatments for gastrointestinal diseases, notably its CIC therapy for carbohydrate malabsorption in humans and animals.
Is ANR a good investment?
ANR is highly speculative due to its micro-cap size and pre-revenue stage. Investment potential hinges on successful trial outcomes and strategic partnerships, balanced against high development risks.
What drives ANR's share price?
Key drivers include clinical trial results, funding announcements, partnership news, and progress in the veterinary market, typical for early-stage biotechs.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$138.50
-44.8% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.91
-24.8% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.00
-20.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.